Novartis Pharmaceuticals – FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)

Access Program Information

The purpose of this study is to provide access to Midostaurin and gather additional safety
data on the combination of Midostaurin and standard of care for adult patients with newly
diagnosed Fms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML) who
are eligible for standard induction and consolidation chemotherapy.

Rare Disease: